Shawn Scott Ledingham, Jr.

Summary — Shawn S. Ledingham, Jr. (Proskauer Rose LLP, Los Angeles)

Specialty / focus. Ledingham is a trial and commercial litigator rather than a career patent specialist. His only tracked patent appearance is defense counsel for Amgen in Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (C.D. Cal. No. 2:24-cv-264), a BPCIA/biosimilar dispute over aflibercept (Eylea) that sits within the broader multidistrict aflibercept patent campaign consolidated in the N.D.W. Va. In that matter he handled preliminary-injunction scheduling and ex parte skirmishing for Amgen. His wider Proskauer practice — Trial Strategies, Product Liability & Consumer Litigation, and Sports Law — is defense-side commercial, antitrust, toxic-tort, and product-liability work across pharma, agriculture, consumer products, and sports. There is no indication of tech-heavy patent work (e.g., Wi-Fi, software, mechanical).

Side preference. Strictly defendant-side in the tracked data (1 defendant appearance, 0 plaintiff), consistent with his broader career defending operating companies: Monsanto/Bayer, Johnson & Johnson, Major League Baseball, T-Mobile, and Sanderson Farms, among others. No NPE/PAE plaintiff work appears.

Firm context and notable matters. Ledingham has spent his entire career at Proskauer Rose (summer associate → associate → senior counsel → partner, promoted November 2022), with no prior firm. Outside the tracked Amgen matter, his most prominent results are defense verdicts in the Roundup mass tort: Stephens v. Monsanto (Dec. 2021 — the first general-causation defense verdict in that litigation) and Alesi v. Monsanto (Sept. 2022, St. Louis). He also helped secure a JNOV overturning a $417 million talc verdict for Johnson & Johnson, won dismissal of San José's antitrust suit against MLB (affirmed through the Ninth Circuit; cert. denied), and was part of the Proskauer team recognized as Law360 "Legal Lions" for the Sanderson Farms broiler-chicken antitrust defense (Oct. 2023).

PTAB / IPR. No public record of IPR/PGR practice; his patent exposure appears confined to district-court biosimilar/BPCIA litigation.

Bar / education. NYU School of Law (J.D., 2010; managing editor, NYU Law Review); California bar (2011); admitted to the Ninth, Second, and Tenth Circuits and the U.S. Supreme Court.